In this model, the addition of an Erk inhibitor to increase PD-L1 levels significantly increased tumor uptake of the full-length antibody 6E11 (compared to vehicle treated control), suggesting Erk inhibition can prime the TME for PD-L1 targeted therapies (20). This evidence concerns the gene CD274 and neoplasm.